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Abstract 12 
The aim of this study was to determine the intramammary dose of benzylpenicillin required 13 
to maintain a concentration in the milk above the MIC for the Gram-positive bacteria that 14 
cause mastitis. The product used in this study was a commercially available procaine 15 
benzylpenicillin in an oily suspension with micronized particles. Three dose levels were 16 
used: 200 000, 300 000 and 600 000 IU. Concentrations of benzylpenicillin in cow milk and 17 
plasma were determined after a single intramammary dose was administered into one 18 
quarter of each of the 5 cows in each treatment group. Samples were analyzed using an 19 
HPLC-MS/MS method which was validated during the study. Concentrations in the milk were 20 
well above the MIC for the target pathogens for all doses tested. There was a linear dose-21 
dependent increase in the mean AUCs of benzylpenicillin concentrations in plasma and milk. 22 
At the first milking, 12 hours after dosing, there was a significant difference between the 23 
mean milk benzylpenicillin concentrations in cows treated with a dose of 600 000 IU, and 24 
those treated with 200 000 or 300 000 IU. Although this study shows a linear relationship 25 
between the dose of procaine benzylpenicillin administered and the concentration in the milk 26 
in the healthy udder, it would be useful to conduct studies on cows with mastitis to define 27 
the optimum dose and duration of intramammary treatment with benzylpenicillin.  28 
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Introduction 31 
Antimicrobial resistance is an emerging issue, so the use of these drugs in food-producing 32 
animals is being scrutinized worldwide (Laxminarayan, Duse et al., 2013). Globally, the 33 
most important indication for antibiotic use on dairy farms is mastitis (Pol & Ruegg, 2007; 34 
Stevens, Piepers et al., 2016). Benzylpenicillin is considered to be the first-line treatment 35 
for mastitis caused by Gram-positive bacteria because of its narrow spectrum, according 36 
to the European Union’s responsible use guidelines (European_Commission, 2015). 37 
Benzylpenicillin is a β-lactam antibiotic with bactericidal action against the major Gram-38 
positive bacteria often found in mastitis, such as Streptococcus spp. and Staphylococcus 39 
spp. (Prescott, 2013). All β-lactam antibiotics have a time-dependent mode of action, 40 
meaning that treatment success mainly depends on the length of time that the drug 41 
remains above the MIC (Turnidge, 1998; Erskine, Wagner et al., 2003; Prescott, 2013) 42 
Intramammary infusion is the most common route of administration for the antibiotics used 43 
to treat mastitis (Gruet, Maincent et al., 2001). The aim of this treatment is to target the 44 
actual infection site by administering the antibiotic into the udder, and for the concentration 45 
of the drug to reach levels above the MIC for the bacteria causing the infection. The active 46 
ingredient must not only distribute well into the milk phase inside the udder, but also be 47 
absorbed into the tissue if the infective agent is an invasive (and potentially intracellular) 48 
pathogen, such as Staphylococcus aureus (Ziv, 1980a). The distribution of penicillin 49 
administered via the intramammary route was investigated in an isolated perfused model 50 
by Ehinger and Kietzmann (2000). Penicillin in oily suspension with small particles 51 
(micronized form) was found to have the best glandular distribution compared to aqueous 52 
solution or oily suspension with large particles. Absorption into the perfusate was also 53 
greatest after treatment with the oily suspension with small particles, delivering the highest 54 
areas under the absorption-time curves (Ehinger & Kietzmann, 2000).  55 
As a result, the decision was taken to use benzylpenicillin in oily suspension with small 56 
particle size to formulate a new intramammary penicillin product. According to the European 57 
Medicines Agency (EMA) guidelines on the conduct of pharmacokinetic studies in target 58 
animal species, the dose of the active substance needs to be determined using the 59 
concentration of penicillin in the milk as a function of time to allow the therapeutic 60 
concentration-time profile at the infection site in the udder to be estimated. The same 61 
procedure should be applied to the plasma to estimate potential systemic absorption. Dose 62 
determination studies usually require three different dose levels to be tested and are typically 63 
performed in healthy animals (EMA, 2000).  64 
The aim of this study was to determine the intramammary dose of benzylpenicillin required 65 
to maintain a concentration in the milk above the MIC for 24 hours for Gram-positive 66 
mastitis pathogens. Concentrations of benzylpenicillin in cow milk and plasma were 67 
measured following a single intramammary administration of benzylpenicillin procaine at 68 
three dose levels (200 000, 300 000 and 600 000 IU) into one udder quarter. The study 69 
was conducted in 2005 and followed the principles of the EMA guidelines for the conduct 70 
of pharmacokinetic studies in target animal species that were in force at the time (EMA, 71 
2000) . The product was originally authorized for use in only a few countries, but in 2017 72 
an identical copy of it was approved for use in fourteen countries of the European Union 73 
through the decentralized procedure. 74 
Materials and Methods 75 
Subjects and product administration 76 
Fifteen clinically healthy, 2 to 5-year-old Holstein cows were selected for this study. The 77 
cows were between the 3rd and 6th month of lactation and had not received any antibiotic 78 
treatment in the 8 days preceding the trial. The average daily milk yield was 32 liters (range 79 
22.9–43.5) at the beginning of the study. All animals were housed on the farm of origin, 80 
which was also the site of the study, but an acclimation period of 7 days was applied to allow 81 
pre-trial observation of the cows. Each cow was examined clinically once daily throughout 82 
the entire acclimation and study phase: udders were inspected and palpated, and milk was 83 
checked for the appearance of clots or flakes, and changes in color and consistency. Milk 84 
production was recorded at each milking. During the acclimation period, the cows were 85 
ranked by lactation stage, then randomly allocated into five lactation stage groups, each 86 
containing three animals, to ensure similar distribution of days in milk across the groups. 87 
Computerized random number generation was performed with Microsoft Excel® (Microsoft 88 
Corporation, Redmond, WA, USA) to randomly allocate one animal out of each lactation 89 
stage group to each of three treatment groups. More details on the animals involved in the 90 
study can be found in Table 1. 91 
Include Table 1 here. 92 
The test product was a registered intramammary suspension (Carepen®, Vetcare Oy, 93 
Mantsala, Finland, also registered as Ubropen®, Boehringer Ingelheim Animal Health, 94 
Germany) containing 600 000 IU (equivalent to 600 mg) of micronized procaine 95 
benzylpenicillin per 10 mL in an oily suspension. The product was administered 96 
intramammarily into the left front quarter. All animals were treated once after the morning 97 
milking on Day 0. For Group 1 (200 000 IU penicillin) and Group 2 (300 000 IU penicillin), 98 
two-thirds and one half, respectively, of the contents of a Carepen® /Ubropen® tube was 99 
discarded before administration to obtain the correct dose of benzylpenicillin procaine per 100 
cow. The full contents of the Carepen®/Ubropen® tube was administered to animals in Group 101 
3. Tubes were weighed before and after administration to determine the actual dose given. 102 
Teats were properly cleaned with individual antiseptic wipes before administration. 103 
 104 
The study was carried out in compliance with French legislation on the protection of 105 
laboratory animals, and in accordance with a valid license for experiments on vertebrate 106 
animals issued by the French Ministry for Agriculture. The study passed the ethical review 107 
committee of Avogadro (Fontenilles, France), the contract research organization that was 108 
responsible for the trial (Reference code of the study: A051143 ). 109 
 110 
Milk and blood sampling 111 
Before dosing, mixed milk samples were collected from all cows on day 0 from the milk 112 
obtained during regular milking. On day 1, milk samples from treated quarters were collected 113 
at 12, 24, 48 and 72 hours after dosing. The foremilk from the treated quarter was discarded 114 
and the teat was thoroughly cleaned and disinfected before each sample was collected. 115 
Three samples of about 5 mL of milk were collected from each treated quarter at each 116 
sampling session. The cow’s total milk yield was also recorded at each sampling session. 117 
Samples were transported to the analytical laboratory (Avogadro, Fontenilles, France) at 118 
about 4 °C and frozen (to about -20 °C) as soon as possible. 119 
Blood samples were collected from the jugular or tail vein before treatment and at 3, 6, 12, 120 
15, 18 and 24 hours after administration. Blood (10 mL) was collected in lithium heparin 121 
tubes which were kept at 4 °C until centrifugation. They were centrifuged at around 2500 g 122 
for 10 minutes at 4 °C and 1.5 mL of plasma from each sample was transferred to each of 123 
3 propylene tubes. 124 
Quantification of benzylpenicillin 125 
Samples were processed by the laboratory within 5 days of arrival. A stability test was 126 
performed, indicating that benzylpenicillin was stable in plasma at -20 °C for at least 9 days 127 
in storage (max. 20% degradation). Samples were analyzed by HPLC-MS/MS after 128 
precipitation of the protein with acetonitrile and solid-phase extraction with an OASIS® HLB 129 
cartridge (Waters Corporation, Milford, MA, USA). The Lower Limit of Quantification (LLOQ) 130 
of the testing method in milk and plasma was 2 ng/mL. For comparison, the Maximum 131 
Residue Limit (MRL) in the European Union is set at 4 µg/kg (or 4 ng/g) for milk (EMA, 1999). 132 
Specificity against endogenous substances was evaluated by carefully assessing the ion 133 
chromatograms from plasma from control cows at the retention times of benzylpenicillin and 134 
phenoxymethylpenicillin (the latter being the internal standard). No interfering peaks were 135 
observed at these times on the ion chromatograms from six control samples. The HPLC-136 
MS/MS method used to determine the benzylpenicillin in bovine milk and plasma was 137 
validated during the assay. Linearity was verified from 2 ng/mL to 400 ng/mL of 138 
benzylpenicillin in plasma. The extraction recovery from 6 spiked plasma samples showed 139 
that benzylpenicillin and phenoxymethylpenicillin were efficiently extracted from bovine 140 
plasma (mean recovery 69.8%, coefficient of variation (CV) 3.9%). The matrix effect after 141 
replicate analyses (n=2) on benzylpenicillin and phenoxymethylpenicillin from plasma was 142 
deemed negligible (-6.3% and +2.7% respectively). The precision and accuracy evaluated 143 
at 3 concentration levels of benzylpenicillin were within an acceptance range. The highest 144 
acceptable CV was set at 20% for the quality control (QC) LLOQ and 15% for other 145 
concentrations. The highest acceptable percentage of error was set at +/- 20% for the LLOQ 146 
and +/- 15% for other concentrations. Milk QC samples would be rejected if the 147 
concentration deviated from the theoretical value by more than -30% to +10%, or if an 148 
unsatisfactory chromatographic peak was obtained, or in the event of a manipulation error. 149 
During each batch analysis, at least 4 of the 6 QC samples were within this range, and at 150 
least 5 calibration points were included in the final calculation of the calibration curve 151 
parameters. Analysis of milk and plasma specimens was deemed acceptable as the 152 
calibration curve and the quality controls included in the analytical batches were within their 153 
respective acceptance criteria.  154 
Data analysis 155 
Statgraphics Plus® (Statistical Graphics, Rockville, USA) was used for statistical analysis for 156 
calibration. The linearity of the response in plasma and milk was evaluated with 3 calibration 157 
curves. Each calibration curve included a blank matrix, a zero matrix and six levels of 158 
concentration (2, 5, 25, 75, 200 and 400 ng of benzylpenicillin per mL of plasma). The 159 
calibration curve was obtained by least-squares regression of the calculated response 160 
versus theoretical concentration using several regression models (untransformed, 1/x, 1/x2). 161 
ANOVA, including the lack-of-fit test, was performed on the regression curve, and linearity 162 
was determined based on examination of the residuals; outliers were checked and discarded 163 
when the absolute value of the residual was above 2. Linear adjustment by the least-squares 164 
mean method with a weighting factor of 1/x2 was determined to be the most appropriate 165 
model to express the relationship between the response and the theoretical concentration 166 
in bovine plasma. One outlier was discarded. 167 
Areas Under the Curve (AUC) were calculated for benzylpenicillin concentrations in blood 168 
and milk using Microsoft Excel®. Concentrations in blood and milk were summarized at 169 
each time point into means and geometric means; the latter to reduce the influence of 170 
possible outliers. Benzylpenicillin concentrations in milk were log-transformed for easier 171 
visual interpretation. Further statistical analysis was performed using SAS® software 172 
version 9.4 (SAS Institute Inc., Cary, NC, USA).  Results were considered significant at 173 
alpha=0.05 level. A simple linear regression model was fitted with AUC as the outcome 174 
variable and “actual administered dose” as an explanatory variable. A non-parametric test 175 
(the Jonckheere-Terpstra test; (Terpstra & Magel, 2003) was also performed at the given 176 
time points to evaluate whether benzylpenicillin concentrations in plasma and milk differed 177 
between treatment groups. Measurements that were below the quantification limit were 178 
treated as zero in the analysis. 179 
Results 180 
No adverse reactions, clinical signs or changes in daily milk production were observed after 181 
treatment. The mean dose of penicillin actually administered to each treatment group is 182 
shown in Table 1.  183 
Concentration in plasma 184 
The mean benzylpenicillin concentrations determined in the plasma over 24 hours are 185 
presented in Figure 1. A linear dose-dependent increase was seen in the mean AUCs for 186 
benzylpenicillin in plasma (corrected by the actual administered dose in IU/kg bodyweight; 187 
p<0.0001) (Figure 2). The Jonckheere-Terpstra test demonstrated that increasing the dose 188 
increased the benzylpenicillin in the plasma at 6, 12, 15 and 18 hours after dosing (p-values 189 
0.0002; <0.0001; 0.0001; and 0.0037 respectively). The concentration in the plasma 190 
dropped below the quantification limit at 24 hours in all dosage regimens (data not shown). 191 
Include Figure 1 and Figure 2 here 192 
Concentration in milk 193 
The mean and geometric mean of benzylpenicillin concentrations in samples of milk from 194 
treated quarters are presented in Table 2. Mean log concentrations of benzylpenicillin in milk 195 
are presented in Figure 3. At the first milking, 12 hours after dosing, there was evidence that 196 
increasing the benzylpenicillin dose administered to the mammary quarter increased milk 197 
benzylpenicillin concentrations (p=0.002 in the Jonckheere-Terpstra test). The difference 198 
was not significant at the second milking, 24 hours after dosing, and fourth milking, 48 hours 199 
after dosing (p=0.234 and p=0.500 respectively). A linear dose-dependent increase was 200 
seen in the mean AUCs of benzylpenicillin concentrations in milk (corrected by the actual 201 
administered dose in IU/kg bodyweight; p=0.046) (Figure 4). 202 
 203 
Include Table 2 and Figure 3 here 204 
Discussion and conclusion 205 
The aim of intramammary benzylpenicillin administration is to achieve concentrations of 206 
the active ingredient above the MIC for the relevant pathogens. These concentrations 207 
should be reached at the site of infection (in the udder) for long enough to eliminate the 208 
infection, while minimizing the exposure of commensal bacteria (such as those found in 209 
the gut) to the drug to reduce the risk of selecting resistant bacteria . We believe that this 210 
is the first validated study on the pharmacokinetics of benzylpenicillin after intramammary 211 
administration. 212 
In Europe, the most relevant Gram-positive udder pathogens isolated in mastitis and treated with 213 
antimicrobials are Staphylococcus aureus and Streptococcus uberis (Tenhagen, Hansen et 214 
al., 2009; Verbeke, Piepers et al., 2014; Santman-Berends, Lam et al., 2015; Vakkamäki, 215 
Taponen et al., 2017). No clinical MIC breakpoints are available for penicillin in bovine 216 
mastitis. The epidemiological breakpoints for the susceptibility of staphylococci (including 217 
S. aureus), group A streptococci (S. dysgalactiae) and group B streptococci (S. agalactiae) 218 
to penicillin are defined by the European Committee on Antimicrobial Susceptibility Testing 219 
(EUCAST) as 0.125 µg/mL. No such breakpoint is available for S. uberis (EUCAST, 2017), 220 
although 0.125 µg/mL is commonly accepted (Thomas, de Jong et al., 2015).    221 
Most mastitis-causing streptococci have remained susceptible to benzylpenicillin 222 
(Hendriksen, Mevius et al., 2008; MARAN, 2008; SVARM, 2010; FINRES, 2015). Reduced 223 
susceptibility has been reported in a small proportion of S. uberis isolates (Haenni, 224 
Galofaro et al., 2010; FINRES, 2015). This finding probably has no clinical relevance, 225 
because the proportion of these isolates remains below 5% and their MIC is still much 226 
below the concentrations achieved by intramammary administration of penicillin (FINRES, 227 
2015). S. aureus has developed penicillin resistance by producing β-lactamase. The 228 
proportion of β-lactamase-positive isolates collected from quarter milk samples of cows 229 
with mastitis in European countries varies from less than 10% to over 50% (Hendriksen, 230 
Mevius et al., 2008; Kalmus, Aasmäe et al., 2011; FINRES, 2015; Thomas, de Jong et al., 231 
2015). Clinical mastitis caused by coagulase-negative staphylococci can also be treated 232 
with penicillin, and resistance among these is more common than in S. aureus (Taponen, 233 
Nykäsenoja et al., 2016). It is remarkable that Scandinavian countries which almost 234 
exclusively treat mastitis with benzylpenicillin have reported consistently very low or 235 
decreasing numbers of penicillin-resistant S. aureus isolates (Pitkälä, Haveri et al., 2004; 236 
Swedres-SVARM, 2014; FINRES, 2015; NORM-VET, 2016). 237 
In the current study, penicillin concentration in the milk compartment exceeded the MIC for 238 
the relevant pathogens for at least 24 hours with all dosages. 24 hours is proposed to be a 239 
good administration interval for an intramammary antibiotic, since it requires only once a day 240 
manipulation of the teat and ensures compliance due to adaptation to different milking 241 
regimes (twice-a-day, three-times-a-day or voluntary milking systems). With the lower dose 242 
of 200 000 IU, the concentration at 24 hours was as much as 20 times greater than the MIC; 243 
with 300 000 IU, 22 times greater; and with 600 000 IU, 70 times greater. Variation in the 244 
600 000 IU group was large, so the geometric mean, which was 35 times greater than the 245 
MIC, may describe the results more accurately.  246 
For time-dependent antibiotics such as benzylpenicillin, maximum kill in vitro is achieved at 247 
3 to 4 times the MIC, and the most important predictor for elimination of infection is the time 248 
above the MIC (Turnidge, 1998). In light of the paradoxically reduced bactericidal activity of 249 
high doses of penicillin (first described by Eagle and Musselman (1948), and known as the 250 
“Eagle effect”), our study indicates that all doses used could possibly be unnecessarily high. 251 
It must be noted that the paradoxically inferior effect of high doses has been observed with 252 
most β-lactam antibiotics, mainly with Gram-positive bacteria, and it is not always 253 
synonymous with the classic Eagle effect (Odenholt-Tornqvist, 1988; Hamilton-Miller & 254 
Shah, 1999). Penicillin has been used to treat mastitis for over 50 years, at lower doses than 255 
at present (Le Louedec, 1978) and early studies showed that doses as low as 100 000 IU 256 
(every milking) resulted in high cure rates (Edwards, 1962; Le Louedec, 1978). However, 257 
the main target pathogen at the time of those studies was S. agalactiae, which responded 258 
very well to treatment (Edwards, 1962).  259 
There are more arguments to support the higher dosing regimen. Some caution is warranted 260 
when interpreting the results, as the only samples taken consisted of foremilk. Studies with 261 
another β-lactam antibiotic (cephapirin) have shown that foremilk contains higher 262 
concentrations of the drug than subsequent milk, potentially overestimating the drug 263 
concentration reached in the entire udder (Stockler, Morin et al., 2009). 264 
The results of the current study also reveal considerable variation in benzylpenicillin 265 
concentrations in milk between cows in the same treatment group. The same finding was 266 
reported by Bjorland, Waage et al. (1998) who compared two intramammary doses of 267 
benzylpenicillin in five cows. Moreover, one target pathogen, S. aureus, is known to 268 
penetrate into udder tissue (Almeida, Matthews et al., 1996), and penicillin is also transferred 269 
into this tissue in the usual pharmacokinetic manner (Ziv, 1980b).  Penicillin concentrations 270 
in udder tissue were not measured in this study, so we can only speculate on the penetration 271 
of penicillin into deeper udder tissue and whether effective concentrations accumulate there. 272 
However, Ehringer and Kietzmann (2000) noticed that the concentration of benzylpenicillin 273 
in the tissue decreased exponentially with increasing vertical distance from the teat base, 274 
and they found that benzylpenicillin concentration in the tissues of the lower part of the udder 275 
was around 1/10th of that of the upper part of the udder. This could be the reason why a field 276 
trial which studied clinical mastitis caused by S. aureus demonstrated significantly better 277 
cure rates when intramammary treatment was supplemented with systemic penicillin, 278 
compared to intramammary treatment alone (Taponen, Jantunen et al., 2003).  279 
Finally, the pharmacokinetics of benzylpenicillin in healthy animals could be significantly 280 
different from cows suffering from mastitis, as the pharmacokinetic properties of active 281 
substances are determined in healthy animals (EMA, 2000). Pathological changes in cows 282 
with clinical mastitis, including swelling and occlusion of the ducts in the mammary gland, 283 
may result in uneven distribution of the drug and the associated risk of lower local penicillin 284 
concentrations (Ullberg, Hansson et al., 1958; Ziv, 1980b). In an experimental S. uberis 285 
infection, inflammatory changes caused widespread occlusion of the mammary gland 286 
secretory system (Pedersen, Aalbaek et al., 2003). Inflammation in the udder changes the 287 
composition of the milk and damages the blood-milk barrier, increasing the permeability of 288 
the blood and milk compartments and potentially accelerating elimination of the drug  289 
(Erskine, Wilson et al., 1995; Zhao & Lacasse, 2008).   290 
In conclusion, our results showed a dose-dependent increase in the concentration of 291 
benzylpenicillin in plasma and milk when applied in an oily suspension with micronized 292 
particles. Although concentrations in the milk after administration of the lower doses were 293 
well above the MIC for the target pathogens, distribution of the active ingredient in the 294 
inflamed udder and the location of the pathogens inside the udder tissue must be taken into 295 
account. For this reason, the suggested dose for this product is the higher dose of 600 000 296 
IU administered once a day. It would be useful to conduct field studies with naturally 297 
occurring intramammary infections to define the optimum dose and duration of 298 
intramammary treatment with benzylpenicillin. 299 
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Tables and figures 432 
Table 1: Mean (and SD) body weight (kg), age (months), days in milk (days) and daily milk 433 
yield (kg) for each of the treatment groups and the theoretical dose of benzylpenicillin. The 434 
last column contains the actual dose of benzylpenicillin given after weighing of the 435 




al dose of   
benzylpen
icillin (IU) 
Cow body weight   
(kg) Age (months) Days in Milk  
Daily milk yield 
(kg) 
Actual dose of 
benzylpenicillin 
(IU) 
Mean         SD Mean SD Mean SD Mean SD Mean SD 
1 200 000 585.4 55.5 40.8 12.3 149.2 34.2 32.3 7.9 189 832.0 4613.0 
2 300 000 622.8 74.2 46.4 14.0 156.2 23.3 32.4 5.1 289 994.0 8404.0 
3 600 000 615.2 43.1 42.8 18.3 151.0 36.7 32.8 7.4 610 244.0 5829.0 
Average    607.8 57.1 43.3 14.2 152.1 29.7 32.5 6.4     
            
 437 
Table 2: Mean, standard deviation and geometric mean of the concentration of 438 
benzylpenicillin (in ng/mL) found in milk after intramammary administration of approximately 439 
200.000 IU, 300.000 IU or 600.000 IU of benzylpenicillin in the form of an oily suspension 440 
with micronised particle size. 441 





















0 5/5 samples below quantification limit 5/5 samples below quantification limit 5/5 samples below quantification limit 
12 35345.24 22572.37 30438.00 41351.25 16982.59 38558.00 103476.36 45736.28 96380.47 
24 2519.24 626.19 2459.06 2843.88 1160.82 2648.71 8778.28 12314.25 4486.51 
48 13.86 10.18 11.19 18.77 19.36 11.12 20.09 8.85 18.37 
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 446 
 447 
Figure 1: Mean benzylpenicillin concentrations in ng/mL (with SEM) determined in plasma 448 
specimens after intramammary administration of approximately 200.000 IU, 300.000 IU or 449 
600.000 IU of procaine benzylpenicillin in the form of an oily suspension with micronised 450 







































  452 
Figure 2: Simple linear regression model of Mean Area Under Curve (AUC) of 453 
benzylpenicillin levels in plasma after intramammary administration of approximately 454 
200.000 IU, 300.000 IU or 600.000 IU benzylpenicillin in the form of an oily suspension with 455 
micronised particle size. The AUC was corrected for the actual administered dose 456 
administered to each cow in IU/kg bodyweight. 457 
 458 
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 460 
461 
Figure 3: Mean benzylpenicillin log concentrations (ng.mL-1) (with SEM) found in quarter 462 
milk samples after intramammary administration of one quarter with respectively 200.000 463 
IU, 300.000 IU and 600.000 IU of benzylpenicillin in the form of an oily suspension with 464 

































Figure 4: Simple linear regression model of Mean Area Under Curve (AUC) of 467 
benzylpenicillin levels in milk after intramammary administration of approximately 200.000 468 
IU, 300.000 IU or 600.000 IU benzylpenicillin in the form of an oily suspension with 469 
micronised particle size. The AUC was corrected for the actual administered dose 470 
administered to each cow in IU/kg bodyweight. 471 
 472 
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